Funding for this research was provided by:
South African Medical Research Council (SAMRC-RFA-IRF-02-2016)
Initiative for Cardiovascular Health Research in Developing Countries (IC Health) Foundation Council (N/A)
Brigham and Women’s Hospital, Harvard University (N/A)
Received: 19 March 2020
Accepted: 12 August 2020
First Online: 27 August 2020
Ethics approval and consent to participate
: Ethics approval was obtained from the South African Medical Research Council’s Human Research Ethics Committee (EC026–9/2016) and the University of Cape Town’s Research and Ethics Committee (224/2006). All participants signed informed consent.
: Not applicable
: The datasets generated during and/or analysed during the current study are not publicly available because further analyses are currently being conducted by the investigators but are available from the corresponding author on reasonable request.
: Naomi Levitt has received honoraria from Novartis for serving on the steering committee for the Navigator Trial and travel support from Novo Nordisk, Eli Lilly Laboratories and Sanofi Aventis. All other authors report no potential conflicts of interest, including specific financial interests, relevant to the subject of this manuscript.
: This work was supported by the South African Medical Research Council (SAMRC): SAMRC-RFA-IRF-02-2016; an unrestricted grant from Servier Laboratories (South Africa); the Initiative for Cardiovascular Health Research in Developing Countries (IC Health) Foundation Council; and Brigham and Women’s Hospital, Harvard University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.